Tesamorelin is a stabilized synthetic analog of GHRH consisting of a 44-amino acid sequence with an added trans-3-hexenoic acid group to enhance stability and bioavailability¹³. By binding to GHRH receptors in the anterior pituitary, Tesamorelin stimulates the natural pulsatile release of GH, leading to downstream increases in insulin-like growth factor-1 (IGF-1)¹⁴⁻¹⁵.
Pharmacologically, Tesamorelin exhibits:
Tesamorelin significantly reduces visceral adipose tissue (VAT) while preserving subcutaneous fat, making it a valuable therapy for individuals with metabolic syndrome, obesity, and HIV-associated lipodystrophy⁴⁻⁶. Clinical trials demonstrate up to a 20% reduction in VAT over six months of treatment⁵.
Emerging research highlights the role of GH and IGF-1 in cognitive performance. Tesamorelin has been shown to enhance executive function, working memory, and neuroplasticity, particularly in aging individuals⁷⁻⁸.
GH and IGF-1 play key roles in muscle anabolism and repair. Studies indicate that Tesamorelin increases lean body mass, enhances muscle protein synthesis, and accelerates recovery from musculoskeletal injuries⁹⁻¹⁰.
Unlike exogenous GH, which can induce insulin resistance, Tesamorelin has been found to maintain or even improve insulin sensitivity in some populations¹⁵⁻¹⁶. Its ability to enhance lipid metabolism contributes to a more favorable metabolic profile.
**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.